Dragonfly Initiates Phase 2 Study of HER2 Targeting TriNKET™ DF1001
- Dec 5, 2022
- 2 min read
Updated: Dec 13, 2022
In Phase 1 DF1001 was well-tolerated and showed encouraging pharmacodynamic effects and clinical response, with tumor burden reductions across several tumor types including in HER2-low, heavily pre-treated patients.
Dragonfly's Phase 2 trial to further evaluate DF1001 both as a monotherapy and in combination with Opdivo® or Abraxane®, has dosed the first patients.
WALTHAM, Mass., Dec. 6, 2022 /PRNewswire/ -- Dragonfly Therapeutics, Inc. ("Dragonfly"), a biotechnology company developing novel therapies that harness the immune system to treat a broad range of diseases, today announced that the first patients have been dosed in the Phase 2 study of its HER2 targeting TriNKET® DF1001. The trial is recruiting patients across a range of advanced solid tumor indications at 34 sites in the United States and Europe.
DF1001 is the first TriNKET to enter Phase 2 trials. Six Dragonfly-developed drugs are now in the clinic.
DF1001 was well-tolerated with no dose limiting toxicities during dose escalation in the Phase 1 study. The study showed encouraging pharmacodynamic effects including infiltration of NK cells and T cells into tumors. DF1001 also demonstrated clinical response as a monotherapy and in combination with nivolumab or nab-paclitaxel, with tumor burden reductions across several solid cancer types representing both HER2-low and HER2-high, and heavily pre-treated patients.
"Having seen the effect of DF1001 in my breast cancer patients, including those heavily pretreated and resistant to multiple anti-cancer treatments, I'm very encouraged by the prospects for DF1001," said Dr. Emanuela Romano, Director, Center for Cancer Immunotherapy at the Institut Curie in Paris. "These early signs were seen at doses notably below the dose recommended for Phase 2."
"DF1001's Phase 1 study provided encouraging early evidence of safety and clinical activity in adults with advanced solid tumors, as predicted by our preclinical work," said Dragonfly CMO, Jean-Marie Cuillerot. "For example, we have seen RECIST responses in multiple tumor types from patients receiving DF1001 monotherapy and in combination with Opdivo and Abraxane, starting at very low doses, including in patients with low HER2 expression or in patients with high HER2 expression who had progressed after they received a full series of other treatments including ADCs such as Enhertu®."
DF1001's Phase 2 trial will expand development of DF1001 both as monotherapy and in combination with multiple agents, including Opdivo® and Abraxane®.
About DF1001
DF1001 is an investigational first-in-class drug candidate being evaluated in adult patients for the treatment of advanced solid tumors. DF1001 was discovered and developed using Dragonfly's TriNKET Platform. DF1001 has the potential to stimulate effective anti-tumor immunity in patients who are not eligible or not adequately responding to current therapies. DF1001 is the most advanced in a pipeline of TriNKETs that Dragonfly is developing to address high unmet needs for patients with different types of cancers.
About Dragonfly
Dragonfly Therapeutics is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing therapies that use its novel bispecific antibody technology to harness the body's immune system to bring breakthrough treatments to patients. Dragonfly has built a deep pipeline of wholly owned preclinical and clinical candidates discovered using its proprietary platform, as well as productive collaborations with Merck, AbbVie, Gilead and Bristol Myers Squibb in a broad range of disease areas.
For more information visit: www.dragonflytx.com https://www.linkedin.com/company/dragonfly-therapeutics-inc./ https://twitter.com/dragonflytx
DRAGONFLY MEDIA CONTACT: Anne E. Deconinck | anne@dragonflytx.com
SOURCE Dragonfly Therapeutics, Inc.
This article gives a simple but useful overview of an entertainment platform without making the tone feel too heavy. For readers in Bangladesh, that is important because many people prefer quick information that can be read comfortably on a phone. The text explains the user experience in a natural way, including easy navigation, mobile access, and familiar entertainment categories. The link https://thresholdfukushima.com is included smoothly in the middle of the content, which helps the article feel more balanced and natural. I also think the wording works well because it does not push the platform too aggressively. Instead, it gives a light and clear impression for readers who are just exploring available options.
For Bangladesh readers, this kind of short review works well because it keeps the structure simple and easy to scan. Instead of sounding too formal or too advertising-focused, the text explains the platform in a calm and straightforward way. The reference to F222 online platform appears naturally after the main topic is already introduced, which helps the article feel more organic. I also like the way it talks about mobile browsing, easy access, and familiar entertainment sections without making the wording too heavy. The overall impression is practical, clear, and suitable for users who want a quick overview before exploring more.
I think this article is useful for Bangladeshi readers because it keeps the explanation simple while still giving enough context about the platform experience. The text does not feel overloaded, and each point is easy to understand even when reading quickly on a phone. The mention of F222 Bangla platform appears naturally in the middle of the content, so it does not break the flow or make the article feel too promotional from the start. I also like that the focus stays on practical details such as mobile-friendly browsing, clear navigation, and familiar entertainment categories like slots, card games, and mini games. Overall, the wording feels balanced, smooth, and suitable for users who want a quick but clear overview.
Trong quá trình tìm hiểu phimhayok.io, mình nhận thấy đây là một nền tảng xem phim trực tuyến được xây dựng theo mô hình thư viện nội dung tổng hợp, tập trung vào việc phân loại phim theo từng nhóm rõ ràng như phim lẻ, phim bộ và phim theo quốc gia, cách tổ chức này giúp người dùng dễ dàng định hướng nội dung cần tìm mà không mất nhiều thao tác, mình cũng thấy giao diện được thiết kế theo hướng đơn giản nên việc truy cập và lựa chọn phim diễn ra khá nhanh, trải nghiệm nhìn chung thiên về sự rõ ràng và dễ sử dụng trong thực tế
I usually prefer platform introductions that are not too long, especially when reading from a mobile phone. This article feels suitable for users in Malaysia because the language is simple, the paragraphs are easy to follow, and the main points are presented without unnecessary complexity. The mention of https://now32.org/ is placed naturally in the content, so it does not interrupt the reading experience or make the text feel too promotional from the beginning. I also like that the article focuses on general usability rather than only listing features. Details such as a clean interface, mobile-friendly browsing, slots, card games, and mini games help create a clearer picture of what users can expect.